TINEA
MCID: DRM011
MIFTS: 50

Dermatophytosis (TINEA)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 77 15 74
Tinea 74 3

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD9CM 36 110 110.9
NCIt 51 C26745
SNOMED-CT 69 47382004
ICD10 34 B35 B35.9

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea corporis and tinea cruris, and has symptoms including fever, pruritus and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Sterol Regulatory Element-Binding Proteins (SREBP) signalling and GPCRs, Class B Secretin-like. The drugs Miconazole and Omeprazole have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells.

CDC : 3 Ringworm poster: Protect Yourself From Itchy Rashes Cdc-pdf[PDF – 1 page]

Wikipedia : 77 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 tinea corporis 33.4 DEFB4A SQLE
2 tinea cruris 33.3 DEFB4A SQLE
3 tinea capitis 33.0 CARD9 KATNAL2
4 candidiasis 30.3 CARD9 DEFB4A
5 oral candidiasis 29.8 DEFB4A LTF
6 tinea nigra 12.5
7 deep dermatophytosis 12.5
8 tinea pedis 12.0
9 tinea unguium 11.8
10 tinea manuum 11.8
11 white piedra 11.8
12 tinea profunda 11.7
13 tinea barbae 11.6
14 dermatomycosis 11.3
15 candidiasis, familial, 2 11.0
16 superficial mycosis 11.0
17 papillomatosis, confluent and reticulated 11.0
18 epidermodysplasia verruciformis 1 11.0
19 ectothrix infectious disease 11.0
20 endothrix infectious disease 11.0
21 tinea imbricata 10.5
22 alopecia areata 10.2
23 dermatitis 10.2
24 seborrheic dermatitis 10.2
25 basal cell carcinoma 1 10.1
26 skin disease 10.1
27 basal cell carcinoma 10.1
28 impetigo 10.1
29 blepharitis 10.1
30 chronic mucocutaneous candidiasis 10.1
31 psoriasis 10.1
32 diabetes mellitus 10.1
33 black piedra 10.1
34 rosacea 10.1
35 discoid lupus erythematosus 10.1
36 lymphoma 10.0
37 urticaria 10.0
38 pemphigus 10.0
39 tinea favosa 10.0
40 kerion celsi 10.0
41 cutaneous lupus erythematosus 10.0
42 cutaneous candidiasis 10.0
43 erysipelas 10.0
44 syphilis 10.0
45 adult t-cell leukemia 10.0
46 leukemia 10.0
47 erythema multiforme 10.0
48 sarcoma 10.0
49 ichthyosis 10.0
50 palmoplantar keratosis 10.0

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Ischemic Heart Disease

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


fever, pruritus, exanthema

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
3
Luliconazole Approved Phase 4,Phase 2,Phase 3,Phase 1 187164-19-8
4
Ciclopirox Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 29342-05-0 2749
5
Amorolfine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 78613-35-1
6
Ketoconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65277-42-1 47576
7
Efinaconazole Approved Phase 4,Phase 3,Not Applicable 164650-44-6
8
carbamide peroxide Approved Phase 4,Phase 3,Not Applicable 124-43-6
9
Bifonazole Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60628-96-8 2378
10
Terbinafine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 91161-71-6 5402 1549008
11
Naftifine Approved Phase 4,Phase 3,Phase 2,Phase 1 65472-88-0 47641 73342
12
Tavaborole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 174671-46-6
13
Itraconazole Approved, Investigational Phase 4,Phase 3,Phase 2 84625-61-6 55283
14
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
15
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
16 Anti-Ulcer Agents Phase 4
17 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antacids Phase 4
19 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Gastrointestinal Agents Phase 4,Phase 3,Not Applicable
21 Proton Pump Inhibitors Phase 4
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Dermatologic Agents Phase 4,Phase 2,Not Applicable
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Keratolytic Agents Phase 4,Not Applicable
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Protective Agents Phase 4,Phase 2,Not Applicable
33 Antioxidants Phase 4,Phase 2,Not Applicable
34 Free Radical Scavengers Phase 4,Phase 2
35
Hydroxyitraconazole Phase 4,Phase 3,Phase 2
36 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Not Applicable
37 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Not Applicable
38 Anti-Bacterial Agents Phase 4,Phase 1,Not Applicable
39 Liposomal amphotericin B Phase 4
40
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
41
Clotrimazole Approved, Vet_approved Phase 3,Phase 1 23593-75-1 2812
42
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
43
Econazole Approved Phase 3,Phase 2 27220-47-9 3198
44
Griseofulvin Approved, Investigational, Vet_approved Phase 3,Not Applicable 126-07-8 441140
45
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
46 Papaya Approved Phase 2, Phase 3
47
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
48
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
49
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
50
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Unknown status NCT02394340 Phase 4 Omeprazole 40mg
2 Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis Unknown status NCT02436291 Phase 4
3 Efficacy, Safety and Cost-effectiveness of a Sequential Therapy With RV4104A Ointment, Ciclopiroxolamine Cream and Ciclopirox Film-forming Solution Compared With Amorolfine Nail Lacquer in Dermatophytic Onychomycosis Unknown status NCT01014637 Phase 4 Amorolfine (Antifungal);RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)
4 An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
6 Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
7 Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
8 Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
9 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
10 Study Evaluating the Effect of Jublia on Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
11 An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents Completed NCT03405818 Phase 4 Tavaborole 5% Topical Solution
12 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish Completed NCT03110029 Phase 4 Efinaconazole 10% Topical Application Solution [JUBLIA]
13 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1% Completed NCT02705664 Phase 4 Loceryl Nail Lacquer;Urea Ointment;Bifonazole Cream
14 Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer Completed NCT02679911 Phase 4 Loceryl NL;Ciclopirox NL
15 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
16 Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish Completed NCT02321098 Phase 4 Loceryl NL + Cosmetic varnish;Loceryl NL 12 weeks;Loceryl NL 15 months
17 Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis Completed NCT01851590 Phase 4 Amorolfine;Terbinafine
18 Topical Penlac Nail Lacquer for Onychomycosis in Children Completed NCT01419847 Phase 4 Ciclopirox;Placebo
19 Scoring Clinical Index For Onychomycosis in Toenail Onychomycosis Treating With Itraconazole Capsules Completed NCT00871728 Phase 4 Itraconazole
20 Topical Amphotericin B in 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis Recruiting NCT03814343 Phase 4 amphotericin B in 30% DMSO;30% DMSO
21 Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis Recruiting NCT03280927 Phase 4 Jublia®
22 Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis Recruiting NCT02812043 Phase 4 Amorolfine
23 Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis Active, not recruiting NCT02812771 Phase 4 Efinaconazole
24 Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children Terminated NCT01646580 Phase 4 ciclopirox
25 Once a Day Topical Treatment for Athlete's Foot Fungus Inbetween the Toes in Males and Females Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
26 Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Unknown status NCT01105013 Phase 3 Clotrimazole
27 Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis Unknown status NCT02961634 Phase 3 Ciclopirox 8%
28 TDT 067 Onychomycosis Study Unknown status NCT01145807 Phase 3 TDT067;Placebo;Transfersome
29 Treating Onychomychosis Unknown status NCT00776464 Phase 2, Phase 3
30 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
31 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
32 Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
33 Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
34 Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis Completed NCT01349998 Phase 3 Product 33525
35 Topical Antifungal Treatment for Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
36 Safety and Equivalence of a Generic Ciclopirox Olamine Cream Compared to the Reference Ciclopirox Cream 0.77% for the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
37 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
38 Topical Antifungal Treatment for Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
39 Efficacy and Safety of Terbinafine Film Forming Solution in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
40 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
41 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
42 Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
43 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
44 Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
45 Safety and Efficacy of Econazole Nitrate Foam 1% in Subjects With Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
46 Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
47 A Study Of Diflucan In Children With Ringworm Of The Scalp Completed NCT00645242 Phase 3 fluconazole
48 BE Study of Naftifine HCL Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
49 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
50 Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

MalaCards organs/tissues related to Dermatophytosis:

42
Skin, Testes, T Cells, Thymus, Brain, Colon, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

20
Nail, Scalp, Glabrous Skin

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 1586)
# Title Authors Year
1
Tinea Versicolor of the Neck As Side Effect of Topical Steroids For Alopecia Areata. ( 30668183 )
2019
2
Dermatophytosis caused by Nannizzia nana in two siblings. ( 30691951 )
2019
3
Widespread Superficial Dermatophytosis in Patient on Secukinumab for Treatment of Chronic Plaque Psoriasis. ( 30775308 )
2019
4
Descriptive epidemiology and test characteristics of cats diagnosed with Microsporum canis dermatophytosis in a Northwestern US animal shelter. ( 30776947 )
2019
5
Nanotechnological interventions in dermatophytosis: from oral to topical, a fresh perspective. ( 30871388 )
2019
6
Efficacy of a rhamnolipid biosurfactant to inhibit Trichophyton rubrum in vitro and in a mice model of dermatophytosis. ( 30908723 )
2019
7
Folliculotropic mycosis fungoides in a pediatric patient mimicking black dot tinea capitis. ( 30791127 )
2019
8
Borderline lepromatous leprosy masking as tinea versicolor. ( 30891732 )
2019
9
Prevalence of Tinea Capitis among Children in Osogbo, Nigeria, and the Associated Risk Factors. ( 30691234 )
2019
10
A case report of tinea capitis in infant in first year of life. ( 30795738 )
2019
11
Extensive tinea capitis and corporis in a child caused by Trichophyton verrucosum. ( 30799183 )
2019
12
A single typical trichoscopic feature is predictive of tinea capitis - a prospective multicenter study. ( 30844082 )
2019
13
Consumer Preferences of Antifungal Products for Treatment and Prevention of Tinea Pedis. ( 30661432 )
2019
14
Risk factors for chronic and chronic-relapsing tinea corporis, tinea cruris and tinea faciei: Results of a case-control study. ( 30719987 )
2019
15
Tinea Imbricata: An Overview. ( 30734680 )
2019
16
Terbinafine-resistant strain of Trichophyton interdigitale strain isolated from a tinea pedis patient. ( 30768808 )
2019
17
Tinea faciei starting at day two of life. ( 30548334 )
2019
18
A "Tinea" immune reconstitution inflammatory syndrome in a HIV-positive patient starting combination antiretroviral treatment. ( 30636396 )
2019
19
Evaluation of the value of staining hair samples with a modified Wright-Giemsa stain and/or showing illustrated guidelines for the microscopic diagnosis of dermatophytosis in cats. ( 29664175 )
2018
20
Comparison of real-time PCR with fungal culture for the diagnosis of Microsporum canis dermatophytosis in shelter cats: a field study. ( 29172910 )
2018
21
Landscape of long non-coding RNAs in Trichophyton mentagrophytes-induced rabbit dermatophytosis lesional skin and normal skin. ( 29560532 )
2018
22
Assessment of a pan-dermatophyte nested-PCR compared with conventional methods for direct detection and identification of dermatophytosis agents in animals. ( 29944743 )
2018
23
Is Antifungal Resistance a Cause for Treatment Failure in Dermatophytosis: A Study Focused on Tinea Corporis and Cruris from a Tertiary Centre? ( 29644192 )
2018
24
Emergence of recalcitrant dermatophytosis in India. ( 29485088 )
2018
25
Indian irrational skin creams and steroid-modified dermatophytosis - an unholy nexus and alarming situation. ( 29706004 )
2018
26
Image Gallery: Molluscum contagiosum-like facial lesions in a patient with a renal transplant: deep dermatophytosis due to Trichophyton rubrum. ( 29785830 )
2018
27
Dermatophytosis in a psoriatic patient treated with secukinumab: an underrated adverse effect? ( 29767491 )
2018
28
Diffuse dermatophytosis occurring on dimethyl fumarate therapy. ( 29649923 )
2018
29
Reinterpreting minimum inhibitory concentration (MIC) data of itraconazole versus terbinafine for dermatophytosis - time to look beyond the MIC data? ( 29243676 )
2018
30
Severe dermatophytosis in solid organ transplant recipients: A French retrospective series and literature review. ( 29094463 )
2018
31
Emergence of recalcitrant dermatophytosis in India. ( 29976522 )
2018
32
Erratum: Intracutaneous pharmacokinetics of oral antifungals and their relevance in recalcitrant cutaneous dermatophytosis: Time to revisit basics. ( 29657191 )
2018
33
Psoriasiform Dermatophytosis in a Bulgarian Child. ( 29484004 )
2018
34
IL-17-Mediated Immunity Controls SkinA Infection and T Helper 1 Response during Experimental Microsporum canisA Dermatophytosis. ( 29571944 )
2018
35
Tinea Capitis Masquerading as Basal Cell Carcinoma. ( 30207532 )
2018
36
Tiefe Trichophytie unter dem Bild einer Blepharitis - Tinea ciliaris. ( 29989360 )
2018
37
IL-17 Takes Center Stage in Dermatophytosis. ( 30032786 )
2018
38
Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). ( 30041646 )
2018
39
A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. ( 30058568 )
2018
40
Erratum for Nagesh et al., phytochemical analysis and docking study of compounds present in a polyherbal preparation used in the treatment of dermatophytosis. ( 30186992 )
2018
41
A clarion call for preventing taxonomical errors of dermatophytes using the example of the novel Trichophyton mentagrophytes genotype VIII uniformly isolated in the Indian epidemic of superficial dermatophytosis. ( 30187579 )
2018
42
A Distinct Clinicopathological Presentation of Cutaneous Dermatophytosis Mimicking Autoimmune Blistering Disorder. ( 30210164 )
2018
43
Th1 and Th17 immune responses act complementarily to optimally control superficial dermatophytosis. ( 30227138 )
2018
44
In vivo antifungal activity of dipyrithione against Trichophyton rubrum on guinea pig dermatophytosis models. ( 30243089 )
2018
45
Diagnosis of dermatophytosis using single fungus endogenous fluorescence spectrometry. ( 30258686 )
2018
46
STAT3 and inherited susceptibility to invasive dermatophytosis. ( 30259966 )
2018
47
Dermatophytosis of the diaper area: Case report and literature review. ( 30284315 )
2018
48
'End of the road for terbinafine' in dermatophytosis: Is it a valid conclusion? ( 30289120 )
2018
49
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release. ( 30292246 )
2018
50
Cover Image: Trichophyton rubrum penetration of horny cells in dermatophytosis. ( 30318795 )
2018

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

Pathways related to Dermatophytosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.82 MBTPS2 SQLE
2 10 ADGRL1 ADGRL2

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cholesterol metabolic process GO:0008203 9.37 MBTPS2 SQLE
2 defense response to Gram-negative bacterium GO:0050829 9.32 DEFB4A LTF
3 antimicrobial humoral immune response mediated by antimicrobial peptide GO:0061844 9.26 DEFB4A LTF
4 antimicrobial humoral response GO:0019730 9.16 DEFB4A LTF
5 killing of cells of other organism GO:0031640 8.96 DEFB4A LTF
6 regulation of cholesterol biosynthetic process GO:0045540 8.62 MBTPS2 SQLE

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 latrotoxin receptor activity GO:0016524 8.62 ADGRL1 ADGRL2

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....